[Clinical results with the antimycotic agent ciclopiroxolamine (author's transl)].
After a brief account of the laboratory and animal studies of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt (ciclopiroxolamine, Cic, Hoe 296, Batrafen) and an outline of previous clinical trials, the results of a double-blind trial with Cic cream and clotrimazole cream are reported, together with those of a large-scale trial of Cic cream in consulting practice. Used for the treatment of skin disorders diagnosed as mycoses, the effectiveness rate of Cic cream ranged from 79 to 98%, depending on the criterion used for assessment. The double-blind trial did not reveal any significant differences between its effect and that of clotrimazole cream. The incidence of side-effects can be regarded as minimal.
D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077768:Ciclopirox; D002986:Clinical Trials as Topic; D003022:Clotrimazole / Q000009:adverse effects / Q000627:therapeutic use; D003881:Dermatomycoses / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use*
D000935:Antifungal Agents; D011728:Pyridones; D000077768:Ciclopirox; D003022:Clotrimazole
Klinische Ergebnisse mit dem Antimykotikum Ciclopiroxolamin.